“You should be able to have that discussion with your own body and your own physician, rather than somebody just removing it as an option for you.” The film puts that pursuit of pleasure in context with a very different medical landscape than when Addyi first premiered, a post-Roe world in which women’s reproductive rights are under assault, healthcare for trans people is criminalized and bodily autonomy across the board remains tenuous. Whether for abortion or orgasm, there’s nothing diminutive or inconsequential about choice, the film concludes. “You might think it’s funny and frivolous to say that women enjoying sex with their husbands is necessary,” said Chin-Yee. “But it is exactly that right being taken away that is related to all the other rights that could be taken away from you, and are being removed in the United States right now.” The Pink Pill is now available on Paramount+ The Pink Pill is now available on Paramount+ There is a reason the fight over a small pink pill feels so enormous. On its surface, The Pink Pill: Sex, Drugs & Who Has Control chronicles the battle to bring a medication for women’s low sexual desire to market. At its core, the documentary is about power.
Opponents of the drug put the onus back on them; one recommended they instead try what worked for her: “switching boyfriends, chocolate, coffee, certain episodes of Grey’s Anatomy, pornography, upgrading my vibrator, read Fifty Shades of Grey, a removable shower-head and an acceptance of myself and the libido I came with”. After much heated back and forth, the FDA approved Addyi in 2015. Eckert subsequently sold Sprout to pharma giant Valeant for $1bn. But the victory came with a major caveat: a black box warning, the most serious level available, for side effects such as dizziness, nausea and headache. Doctors had to take a test to prescribe it.
Pharmacists had to take a test to fildena 120 fill it. Women prescribed Addyi had to sign a pledge that they would not drink alcohol. (Viagra, on the other hand, came with a recommendation that one merely should avoid alcohol.) Faced with declining sales, Valeant more than doubled the price of Addyi, to $800 a prescription, making the drug cost-prohibitive. Then, in 2017, they shelved it altogether. What had once been the promising frontier in female sexual health was now essentially locked away. It is about who gets to define health, who gets to claim pleasure, and who benefits when women are told to stay quiet about their bodies. Women all wonder, “What happened to me?” Men always get listened to.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Generic | 40mg | 60 + 6 Pills | 130.98€ 124.74€ | |
| Viagra Generic | 50mg | 270 + 8 Pills | 198.48€ 189.03€ | |
| Cialis Super Active | 20mg | 90 + 10 Pills | 314.14€ 299.18€ | |
| Viagra Original | 100mg | 8 Pills | 59.84€ 56.99€ | |
| Levitra Original | 20mg | 12 Pills | 81.99€ 78.09€ | |
| Cialis Black | 80mg | 270 + 10 Pills | 502.88€ 478.93€ | |
| Viagra Generic | 50mg | 360 + 10 Pills | 225.33€ 214.60€ | |
| Kamagra Gold | 50 mg | 180 + 6 Pills | 371.27€ 353.59€ | |
| Kamagra Gold | 50 mg | 84 + 6 Pills | 224.77€ 214.07€ | |
| Levitra Original | 20mg | 8 Pills | 65.05€ 61.95€ | |
| Cialis Generic | 10mg | 120 + 6 Pills | 178.49€ 169.99€ | |
| Priligy Generic Dapoxetine | 60mg | 180 + 10 Pills | 494.76€ 471.20€ | |
| Cialis Generic | 10mg | 60 + 6 Pills | 105.81€ 100.77€ | |
| Cialis Generic | 2.5mg | 20 Pills | 40.73€ 38.79€ | |
| Levitra Generic | 10mg | 120 + 10 Pills | 178.59€ 170.09€ | |
| Kamagra Polo | 100mg | 272 + 12 Pills | 622.94€ 593.28€ |
Women are dismissed and made to feel wrong for even asking the question. Directed by Aisling Chin-Yee and premiering at DOC NYC, the film follows entrepreneur Cindy Eckert’s decade-long struggle to win FDA approval for Addyi, the drug frequently labeled “female Viagra.” The nickname is catchy.
| Age Range | Percentage of Users | Main Reasons for Use | Average Duration of Use |
|---|---|---|---|
| 25-35 years | 40% | Mood improvement, libido boost | 3-6 months |
| 36-45 years | 35% | Menopause symptoms, energy enhancement | 6-12 months |
| 46-50 years | 25% | Hormonal support, sleep aid | Varies |
| All ages | N/A | General wellness | Ongoing |
More than twenty medications for male erectile dysfunction have been approved with relative efficiency. Addyi was stalled, scrutinized, and moralized for years. Why do we want horny women running around?
A hyper-feminine, distinctly 2010s entrepreneur with a fondness for everything magenta, Eckert renamed the drug Addyi after Dr Addison Grey, Kate Walsh’s character on the popular medical drama Grey’s Anatomy who represented the drug’s ethos of, as she says, “women living life on their own terms”. Her company, Sprout Pharmaceuticals, completed the necessary trials, demonstrating that Addyi improved the sexual drive and experiences of women struggling with HSDD. By October 2013, it was ready to go to market, subject to FDA approval. Though Addyi works on neurotransmitters in the brain, akin to an antidepressant, the FDA assigned its review to its urology division – a better fit for Viagra, which relaxes muscles and increases blood flow to the male genitalia. The FDA rejected it, claiming that the side effects – namely dizziness, nausea, fatigue and low blood pressure – did not outweigh the benefits.
The question of side effects – essentially, why would desire be worth it for women? – continued to dog the medication as it sought regulatory. The Pink Pill amasses a significant recent history archive of the “female Viagra’s” role in the culture wars of the 2010s, as Sprout mounted an aggressive lobbying campaign ahead of its 2015 hearing. Some of the backlash was predictably patronizing: “You might know [flibanserin] by its old name – wine,” joked Jimmy Fallon on The Tonight Show. Some was more grounded, such as pushback from those who believed HSDD to be a fictional condition to guilt women for their lack of sex drive, low libido medicalized in the name of pharmaceutical profit, with no medical consensus on what constitutes “normal” sexual desire. You want to throttle the lot as you watch. From the beginning, the film establishes the central injustice.
Male sexual performance is framed as essential blue tablets to identity. If a man cannot perform, it is treated as a crisis of masculinity and a medical emergency.
If a woman cannot orgasm, feels pain during intercourse, or loses desire, she is told it is normal. It exposes how medical education and healthcare institutions have long sidelined women’s sexual needs. These same systems have aggressively funded and fast-tracked drugs for men.
“How can you possibly pass something that is so wonderful for women and then have it ripped out?” says Gattuso in the film. “After all of this work, all of this emotion, we’re down to square one again. Eckert managed to buy Addyi back from Valeant and start over. The drug is back on the market – though, if you google it, the first thing you will read is still a bold warning about side effects. Addyi proponents see a seriously stubborn double standard.
There are 26 drugs approved for male sexual dysfunction, Chin-Yee noted, in part because no drug fits all. “That’s obvious, but for this drug and for women, it’s like, ‘well, if this could be a potential side effect, then the risk isn’t worth the benefit,’” she said. “And the benefit is only that women might enjoy their sex better. You know how many drugs come with nausea and dizziness and headaches? Those are things that pretty much every drug has on the side of their box.” The through line, she emphasized, is choice. The film shows regulators raising concerns that women might become drowsy and fall asleep while driving children to school. The subtext is unmistakable: a woman’s primary role is caretaker. Her pleasure is secondary and deeply suspect. What makes the documentary especially urgent is its timing. Chin-Yee situates Eckert’s fight within a broader political shift. Footage of the 2016 election, the reshaping of the Supreme Court, and the fall of Roe v Wade is not incidental. As the political right has gained power, reproductive rights have narrowed. Conversations about contraception and bodily autonomy have become battlegrounds. Movements that seek to limit women’s control over reproduction often also resist conversations about female desire. In conservative and religious circles, sexuality is frequently tethered to procreation and marriage. Female pleasure outside those boundaries is framed as indulgent, destabilizing, even sinful.
Throughout history, many religious doctrines have treated women’s sexuality as something to regulate. Modesty codes, purity culture, and rigid gender roles are not fringe ideas. They are embedded in institutions that shape law and policy. The recent rise of right-leaning political movements has amplified these frameworks. The idealized “tradwife” narrative celebrates domestic submission, childbearing, and withdrawal from public power. Against that backdrop, a drug designed to enhance female desire becomes more than medicine.
The Pink Pill makes clear that resistance to Addyi was not solely about clinical data.
The FDA questioned the potential for sedative effects, wondering if “a woman might take flibanserin the night before and get up the next morning and fall asleep taking her kids to school”, recalls Dr Anita Clayton, a University of Virginia psychiatrist and consultant to Addyi, in the film. “There was a very paternalistic attitude.” Data showing an increase of one “successful sexual event” per month was dismissed as ineffective – even though women with untreated HSDD experienced maybe one or two such events a year. The bias showing through the FDA approval process boiled down to “well, we just don’t know if [Addyi] is necessary’”, said Chin-Yee. “But that’s not a question that has ever come up when it comes to male sexual dysfunction. It is absolutely imperative that if you are a man with a penis, you should be able to do whatever you want with it.
And those were not the same considerations for women.” (The FDA, which denied any accusations of gender bias, did not respond to the film-makers’ interview requests. “I will give the benefit of the doubt to the FDA that they were in the midst of like getting Doge-ed,” Chin-Yee said, referring to the Elon Musk-led consolidation that gutted the department.) Never mind that many women wanted their desire back, and felt less whole without it. “I thought ‘well, after you have kids, that goes away …’” says one HSDD patient in the film, frustrated by her lack of options and a prevailing narrative that “you’re a mother now and you focus on these things. That’s behind you.” The loss of sexual desire was “devastating”, says another whose menopause torched her formerly steady libido. “I felt like someone had slayed me.” Both Gattuso and her daughter testified at the FDA’s public hearing on the drug’s approval, speaking emotionally about the toll their diminished libido had taken on their lives. Discomfort with the idea that women might seek sex for pleasure rather than obligation. Discomfort with acknowledging that female libido is not automatically extinguished by age, motherhood, or long-term partnership. Discomfort with women naming dissatisfaction and demanding solutions. Fear sits at the center of this discomfort. Fear that sexual agency disrupts traditional hierarchies.